Skip to content Accessibility statement

University takes part in global Covid vaccine trial

News

Posted on Wednesday 5 May 2021

The University of York is hosting a trial of a new COVID-19 vaccine.
Around 150 people, aged between 18 and 40 who have not already had a vaccine for COVID-19 will take part in the York trial.

York is one of nine locations across the UK taking part in the global trial which is a first for the city. The University is working with York and Scarborough Teaching Hospitals NHS Foundation Trust and Tees, Esk and Wear Valleys NHS Foundation Trust to deliver the trial.

 The vaccine study will involve a total of 30,000 adult subjects globally. In York around 150 people, aged between 18 and 40 who have not already had a vaccine for COVID-19, will take part in the trial. 

Clinic 

The study will also involve Regional Clinical Research Network partners. The trial will involve up to 10 planned visits to the clinic over a two-year period, but this may be shorter depending upon the on-going results. 

 Professor Charles Lacey from the Hull York Medical School is the Principal Investigator leading the team in York. 

 Professor Lacey said: “Clinical studies are important for medical advances. Current available vaccines are only available because of research study volunteers. Although there are several approved COVID-19 vaccines available, research is ongoing to provide more options, since all vaccines may work differently in providing protection against COVID-19. The vaccine we are trialling showed very exciting results in phase 1/2 studies.”  

 Research

 Lydia Harris, Head of Research and Development at York and Scarborough Teaching Hospitals NHS Foundation Trust, said: “York is rapidly expanding its research capabilities.  The quality of our researchers, facilities and patient groups are allowing us to engage effectively in cutting edge research at an international level.  We have come a long way in a very short period of time.” 

“Our staff are doing incredible work to support COVID-19 research studies and we are very proud to have made significant contributions to this global effort.   

“We’re really proud to be contributing to so many different studies for COVID-19. Our success in these areas has led to us being invited, as part of a cross Clinical Research Network (CRN) collaboration with additional resources being provided by the University of York and Tees, Esk and Wear Valleys NHS Foundation Trust, to take part in a unique COVID-19 vaccine trial.” 

Researchers will compare a placebo vaccine with the study vaccine, with participants crossing over during the trial and receiving both. Participants will not know when they are receiving the placebo or the investigational vaccine. 

Research newsletter

Our monthly research newsletter features a curated mix of news, events, and recent discoveries delivered straight to your inbox.

Sign up

Explore more news

News

7 April 2026

Reducing population vulnerability is just as critical as cutting toxic air emissions for saving lives, according to the findings of a new study.

News

2 April 2026

In one of the largest releases of its kind, almost 16 million records have been made available online - chronicling the personal tragedies and everyday lives of Yorkshire people across nearly seven centuries.

News

1 April 2026

The University of York’s key community partner, York Cares, has been selected by Lord Mayor Elect, Cllr Margaret Wells, as her official charity for the year ahead.

News

31 March 2026

Scientists at the University of York have cracked a 40-year-old biological cold case by revealing how the parasite that causes Sleeping Sickness stays one step ahead of the human immune system.

News

26 March 2026

A University of York academic has been appointed to the panel of a public inquiry investigating the violent confrontation between police and striking miners at Orgreave coking plant in South Yorkshire in June 1984.

Read more news

Our response to the coronavirus pandemic

We're working with partners in York and further afield as part of a global effort to fight the COVID-19 virus. From covid analysis in the labs to producing face shields for the frontline, we're using our knowledge and expertise to support the effort.